Jefferies: CollaGenex, Forest Labs beat Q3 estimates; Connetics lags behind

By Lisa Kerner

Charlotte, N.C., Oct. 9 - In his specialty pharmaceutical prescriptions report, Jefferies & Co., Inc. analyst David Windley said Endo Pharmaceuticals Holdings, Inc. needs a strong fourth-quarter performance from Opana/Opane ER in order to meet the $20 million to $30 million sales guidance for the franchise.

Meanwhile, Cephalon Inc.'s Provigil grew by 18.5% year-over-year and met third-quarter expectations of 676,000 prescriptions. Windley predicted that the drug will grow at a similar rate in the fourth quarter.

The number of prescriptions for Noven Pharmaceuticals Inc.'s Daytrana increased by 6% to over 100,000 in its first full quarter on the market. The drug's weekly growth had been in the teens during July and August.

CollaGenex Pharmaceuticals, Inc.'s total number of prescriptions hit 3,545 for the week ended Sept. 29, partially reversing a 25% decline for the previous week. Oracea beat the analyst's third-quarter forecast of 20,000 prescriptions by roughly 35%.

Two large drugs from Forest Laboratories, Inc., Lexapro and Namenda, finished slightly ahead of Windley's third-quarter forecast, while Connetics Corp. saw three of its four products (OLUX, Luxiq and Evoclin) miss third-quarter forecasts.

Both Barr Pharmaceuticals, Inc. and Watson Pharmaceuticals, Inc. began selling generic versions of Actiq, with meaningful data for these products and Fentora expected next week.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.